Passage Bio Just Lost 75% of Its Team. The FDA Letter That Broke Them.

The company filed an SEC notice on April 28 projecting about $3.3 million in severance and exit costs, with most cuts happening through Q2 and Q3 of 2026. That's not a restructuring. That's a wind-down with a polite name.

A Broader Gene Therapy Reckoning

Passage Bio isn't dying alone. The gene therapy sector has been bleeding talent and money for over a year now, and the reasons form a familiar pattern: sky-high development costs, tiny patient populations, and an FDA that's gotten increasingly cautious about long-term safety.

Consider the recent body count. Rocket Pharmaceuticals cut 30% of its staff in July 2025 after a patient died in a gene therapy trial. Voyager Therapeutics laid off 30 people in December when Novartis returned two of its programs.

The common thread? Gene therapy promised cures, but delivering on that promise turns out to be extraordinarily difficult when regulators (understandably) demand rigorous proof of safety over years or decades.

The Tumor That Spooked Everyone

It's worth understanding why the FDA has gotten so cautious. In January 2026, REGENXBIO revealed that a child treated with its AAV-based gene therapy RGX-111 developed a brain tumor roughly four years after a single dose. The tumor was linked to the viral vector integrating near a cancer-promoting gene called PLAG1.

The child was asymptomatic; the tumor was caught on a routine MRI and successfully removed. But the signal sent shockwaves through the field. The FDA slapped clinical holds on two REGENXBIO programs and issued new guidances on long-term safety monitoring. Every company using AAV vectors (including Passage Bio) suddenly faced a higher bar.

This doesn't mean Passage Bio's therapy caused any similar problems. Its safety profile in nine patients has been clean. But the regulatory environment shifted beneath its feet, and for a company already stretched thin, that shift was fatal.

What's Left on the Table

Passage Bio isn't technically dead yet. Beyond PBFT02 for FTD, there's PBGM01 for GM1 gangliosidosis (a devastating childhood disease). The company says it's exploring partnerships, licensing deals, or outright sales of these programs.

The intellectual property traces back to the University of Pennsylvania's Gene Therapy Program, one of the most respected labs in the field. That pedigree might attract buyers. A larger company with deeper pockets could theoretically pick up PBFT02 and run the randomized trial the FDA demands.

But "might" is doing a lot of heavy lifting in that sentence. Analyst price targets have cratered, with some forecasting the stock could fall as low as $2.39 over 2026. When analysts start using numbers that small, they're not really forecasting; they're writing an obituary.

The Uncomfortable Question

Was the FDA wrong to demand a randomized trial? It's a genuinely hard question. The early data showed biological activity. Patients' brains were shrinking more slowly. Progranulin was being produced. For a uniformly fatal disease with no alternatives, you could argue that's enough to take a chance.

But regulators have been burned before by therapies that looked great in small, uncontrolled studies and fell apart under rigorous testing. The FDA's job isn't to greenlight hope; it's to greenlight evidence. And for Passage Bio, producing that evidence required resources it simply didn't have.

What we're left with is a company born from world-class science, carrying genuinely promising early data, that ran headfirst into the cold economics of rare disease drug development. The therapy might work. We just might never get to find out, unless someone else picks up where Passage Bio left off.

Six people remain at a company that once dreamed of curing dementia with a single injection. That's not a restructuring story. That's a eulogy for a bet that almost paid off.